SYDNEY, Sept. 29, 2014 /PRNewswire/ -- Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) CEO & Chairman, Dr Graham Kelly, conducted an interview with ABC TV that was broadcast on Saturday September 27th during the national 7.00 pm news bulletin and on the following day on Weekend Breakfast. The interview concerned the Company's efforts in bringing its drug candidate, Trilexium, into the clinic in Australia for the treatment of primary brain cancers such as glioblastoma multiforme.

The interview provides certain new information and is being announced to the market today for that reason.

The interview discusses the Company's super-benzopyran anti-cancer drug technology and the collaboration with Yale University that revealed the ability of this family of molecules to kill cancer stem cells, the cells responsible for tumor recurrence after radiotherapy and chemotherapy. Studies then conducted at Weill Cornell Medical College in New York extended this finding by identifying a particular molecule with high potency against glioblastoma cancer stem cells. That molecule has been formulated into the product, Trilexium, intended to treat cancers of neural origin including primary brain cancers in adults and children and neuroblastoma in children.

Sydney-based medical oncologist, Professor Paul De Souza of the University of Western Sydney and Liverpool Hospital, has been appointed Principal Investigator to conduct a Phase 1 clinical study of Trilexium.

The interview can be found at the following address:
www.novogen.com/news/2014/9/28/ceo-graham-kelly-interview-on-abc-television

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT -- based joint venture company, CanTx Inc, with Yale University. NOVOGEN LTD -- ACN 063 259 754 16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0) 2 9472 4100 - F: +61 (0) 2 9476 0388 | www.novogen.com

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

About CanTx

CanTx Inc is a private biotechnology company based in New Haven, Connecticut, and established as a joint venture between Novogen and Yale University. CanTx is dedicated to the development of anti-cancer drugs for the treatment of ovarian cancer.

Further information is available on the Company's website, www.novogen.com
And www.can-tx.com

For more information please contact:

Corporate Contact
Executive Chairman & CEO
Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2-9472-4100

Media Enquiries
Operations Manager
Novogen Group
Cristyn.Humphreys@novogen.com
+61 (0) 2-9472-4111

Investors Enquiries
Executive Chairman & CEO
Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2-9472-4100

SOURCE Novogen Ltd.